Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-08-23
2009-11-24
Szperka, Michael (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S388250, C435S007100, C435S007920, C435S326000, C435S331000
Reexamination Certificate
active
07622558
ABSTRACT:
The invention relates to antibodies which are directed against the FSAP Marburg I variant and to their preparation and use, in particular in therapy and diagnosis. The antibodies are characterized by the fact that they bind specifically to the FSAP MR I variant but not to the FSAP wild-type protein or other mutant variants which are characterized by amino acid substitutions at other positions in the FSAP protein.
REFERENCES:
patent: 3996345 (1976-12-01), Ullman et al.
patent: 4448908 (1984-05-01), Pauly et al.
patent: 4563431 (1986-01-01), Pauly et al.
patent: 4945146 (1990-07-01), Kapmeyer et al.
patent: 5183766 (1993-02-01), Kapmeyer
patent: 5340716 (1994-08-01), Ullman et al.
patent: 5545834 (1996-08-01), Singh et al.
patent: 6831167 (2004-12-01), Roemisch et al.
patent: 2002/0142316 (2002-10-01), Roemisch et al.
patent: 2003/0124622 (2003-07-01), Roemisch et al.
patent: 100 23 923 (2000-12-01), None
patent: 0 080 614 (1983-06-01), None
patent: 0 227 054 (1987-07-01), None
patent: 0 246 446 (1987-11-01), None
patent: 0 411 945 (1991-02-01), None
patent: 0 515 194 (1992-11-01), None
patent: 0 952 215 (1999-10-01), None
patent: 1 182 258 (2002-02-01), None
patent: WO 95/06877 (1995-03-01), None
patent: WO 95/25172 (1995-09-01), None
Romisch et al., Haemostasis 29: 292-299 (1999); The FVII Activating Protease Cleaves Single-Chain Plasminogen Activators.
Willeit et al., Circulation 107, pp. 667-670 (2003), Marburg I Polymorphism of Factor VII—Activating Protease, A Prominent Risk Predictor of Carotid Stenosis.
Larrick et al., Human Antibodies and Hybridomas, 2: 172-189 (1991), “Recombinant Antibodies”.
Bailey et al., Journal of Pharmaceutical & Biomedical Analysis 5: 649-658 (1987), “On The Use of Fluorescent Labels In Immunoassay”.
Udenfriend et al., Proc. Natl. Acad. Sci. 82:8672-8676 (1985), “Scintillation Proximity Radioimmunoassay Utilizing I-Labeled Ligands”.
Gerard Mathis, Clin Chem. 39(9): 1953-1959 (1993), “Rare Earth Cryptates and Homogeneous Fluoroimmunoassays With Human Sera”.
Ullman et al., Clinical Chemistry 42(9): 518-1526(1996), “Luminescent Oxygen Channeling Assay (LOCI™): Sensitive, Broadly Applicable Homogeneous Immunoassay Method”.
Ullman et al., Proc. Natl. Acad. Sci 91: 5426-5430 (1994), “ Luminescent Oxygen Channeling Immunoassay: Measurement Of Particle Binding Kinetics By Chemiluminescence”.
James P. Tam, Proc. Natl. Acad. Sci. USA 85: 5409-5413 (1988), “Synthetic Peptide Vaccine Design: Synthesis and Properties Of A High-Density Multiple Antigenic Peptide System”.
McCafferty et al., Nature 348: 552-554 (1990), “Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains”.
Kevin S. Johnson et al., Human Antibody Engineering, pp. 564-571 (1993), “Current Opinion In Structural Biology”.
Kazuaki Kitano et al., Applied Microbiology and Biotechnology, 24: 282-286, (1986), “Production Of Human Monoclonal Antibodies By Heterohybridomas”.
Keith M. Thompson et al., Journal of Immunological Methods 94: 7-12 (1986), “The Efficient Production Of Stable, Human Monoclonal Antibody-Secreting Hybridomas From EBV-Transformed Lymphocytes Using The Mouse Myeloma X63-Ag8.653 As A Fusion Partner”.
Rainer Fischer et al., Biol Chem, vol. 380: 825-839 (1999), “Molecular Farming Of Recombinant Antibodies In Plants”.
Andrew Hiatt et al., Genetic Engineering, vol. 14: 49-64 (1992), “Assembly Of Antibodies And Mutagenized Variants In Transgenic Plants And Plant Cell Cultures”.
S. Shangary et al., “Peptides Derived from BH3 Domains of Bcl-2 Family Members: A Comparative Analysis of Inhibition of BCL-2, BCL-xLand Bax Oligomerization, Induction of CytochromecRelease, and Activation of Cell Death,”Biochemistry, 41: 9485-9495 (2002).
E. S. Burstein et al.,“Amino Acid Side Chains That Define Muscarinic Receptor/G-protein Coupling,”J. Biol.Chem., 271: 2882-2885 (1996).
J. Roemisch et al., “Quantitation of the Factor VII- and single-chain plasminogen activator-activating protease in plasmas of healthy subjects,”Blood Coag. and Fibrinol., 12: 375-383 (2001).
Althaus Harald
Fischer Bodo
Schwarz Herbert
Wissel Thomas
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Siemens Healthcare Diagnostics Products GmbH
Szperka Michael
LandOfFree
Antibodies which are directed against the Marburg I... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies which are directed against the Marburg I..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies which are directed against the Marburg I... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4131910